David Younger
David Younger is the Co-Founder and CEO of A-Alpha Bio, a Seattle-based biotechnology company applying synthetic biology and machine learning to engineer and predict protein-protein interactions. He is a co-inventor of the AlphaSeq platform, which enables quantitative measurements used in therapeutic antibody and molecular glue discovery. He previously worked as a postdoctoral researcher at the University of Washington.
BioBead Wins $25,000 BECU Grand Prize as Dempsey Startup Awards Distribute Record $92,500 to Student Ventures
The 29th Dempsey Startup Awards awarded a record $92,500 to student entrepreneurs across the Cascadia region, with University of Washington’s BioBead winning the $25,000 BECU Grand Prize for a biodegradable soil probiotic aimed at restoring soil health and improving crop yields.
Trump-Era Funding Cuts and Hiring Freeze Stall UW Protein Design Startups Led by Nobel Laureate David Baker
The University of Washington's Institute for Protein Design, led by Nobel laureate David Baker, faces a hiring freeze and funding cuts under the Trump administration, stalling its promising protein design startups and reducing opportunities for graduate students and postdocs. Despite Nobel-driven interest and advances in AI-designed proteins, budget constraints threaten future innovation and company spinoffs.
Madrona Ventures Invests in Vilya to Develop AI-Designed Macrocycle Drugs Using IPD Tools
Madrona announces its investment in Vilya, which uses AI and computational protein design tools from David Baker’s Institute for Protein Design to generate novel macrocycle drugs that aim to combine oral dosing and high bioavailability with large binding surfaces to target diseases like cancer, inflammation, and neurodegeneration.
Organizations
See all 4-
A-Alpha Bio Executive Officer, Director 2019–present, Chief Executive Officer & Co-Founder 2017–present · current
-
University of Washington Postdoctoral Researcher 2017–2018, Bioengineering Graduate Student 2012–2017 · past
-
Luminex Corporation Engineering Intern 2011 · past
Education
-
University of Washington Doctor of Philosophy (PhD), Bioengineering · 2012–2017
-
Rice University Bachelor of Science; Bachelor of Arts, Bioengineering, Economics · 2007–2012
-
The London School of Economics and Political Science (LSE) Economics · 2009–2010
Online
Questions about David Younger
Who is David Younger?
David Younger is CEO and co-founder of A-Alpha Bio, a role held since 2017. David previously worked as a postdoctoral researcher at University of Washington from 2017 to 2018 and as a bioengineering graduate student there from 2012 to 2017.
What is David Younger known for?
David Younger is a co-inventor of AlphaSeq, a platform for quantitative protein-protein interaction measurements used in therapeutic antibody and molecular glue discovery. David's work at A-Alpha Bio applies synthetic biology and machine learning to engineer and predict protein-protein interactions.
Which organizations is David Younger associated with?
David Younger is associated with A-Alpha Bio as CEO and co-founder from 2017 to present and executive officer from 2019 to present. David was a postdoctoral researcher at University of Washington from 2017 to 2018 and a bioengineering graduate student from 2012 to 2017. David also worked as an engineering intern at Luminex Corporation in 2011 and an intern at Seattle Biomedical Research Institute in 2007.
Where did David Younger study?
David Younger earned a Doctor of Philosophy (PhD) in Bioengineering at University of Washington from 2012 to 2017. David studied Bioengineering and Economics at Rice University from 2007 to 2012, earning a Bachelor of Science and a Bachelor of Arts. David also studied Economics at The London School of Economics and Political Science (LSE) from 2009 to 2010.
Where is David Younger based?
David Younger is based in Seattle, Washington, United States.